What is Trevena's stock symbol?
Trevena trades on the NASDAQ under the ticker symbol "TRVN."
Where is Trevena's stock going? Where will Trevena's stock price be in 2017?
13 brokers have issued 12-month price targets for Trevena's shares. Their predictions range from $8.00 to $18.00. On average, they expect Trevena's share price to reach $12.69 in the next year.
When will Trevena announce their earnings?
Trevena is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.
What are analysts saying about Trevena stock?
Here are some recent quotes from research analysts about Trevena stock:
According to Zacks Investment Research, "Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. " (2/25/2017)
- HC Wainwright analysts commented, "Following the Phase 3 pivotal APOLLO readouts, and the subsequent ~45% drop in TRVN shares (vs. -1.5% NBI) over the last two trading sessions, we assess the implications of the mixed data set, and suggest likely/ probable clinical settings for use that best match OLINVO's (new brand name for oliceridine) overall therapeutic profile' we believe some physicians may find OLINVO useful at reducing antiemetic use, especially in hard tissue pain (most commonly, knee and hip surgery). Yet despite a more nuanced view than some, we nonetheless acknowledge that APOLLO results are far from the "clean win" we were hoping for." (2/23/2017)
- Aegis analysts commented, "After presenting results yesterday, Trevena finished the trading day down approximately 40%. We believe there are several contributing factors: (1) the lowest dose 0.1 mg did not prove non-inferiority to that of morphine; (2) on the safety side, improvements on the respiratory and nausea/vomiting measurement did not show statistical significance to that of Morphine; (3) investors may think that the current data set points to an Oliceridine that has no commercial value proposition relative to that of morphine. This could lead to slow market adoption; (4) the company may need a capital raise before the NDA is accepted. If a capital raise is completed with current share price, this may lead to excessive dilution; (5) the Athena open label study may be a little behind schedule which puts further pressure on cash runway of the company. We will be buyers on weakness. We view the situation quite differently. The most important thing in our eye's is that Trevena is likely to have enough data for an NDA in 4Q17 after the Athena trial is completed." (2/22/2017)
Cowen and Company analysts commented, "TRVN reported top-line results from the pivotal Ph3 APOLLO trials of oliceridine in." (2/21/2017)
Who owns Trevena stock?
Trevena's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (12.87%), Vivo Capital LLC (3.30%), State Street Corp (1.35%), Putnam Investments LLC (0.82%), Harbourvest Partners LLC (0.60%) and Numeric Investors LLC (0.21%). Company insiders that own Trevena stock include Carrie L Bourdow, David Soergel, Maxine Gowen and Yacoub Habib.
Who sold Trevena stock? Who is selling Trevena stock?
Trevena's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Putnam Investments LLC, AQR Capital Management LLC, Metropolitan Life Insurance Co. NY and Guggenheim Capital LLC.
Who bought Trevena stock? Who is buying Trevena stock?
Trevena's stock was purchased by a variety of institutional investors in the last quarter, including Numeric Investors LLC, Russell Investments Group Ltd., State Street Corp, Ellington Management Group LLC and National Planning Corp. Company insiders that have bought Trevena stock in the last two years include Carrie L Bourdow, Maxine Gowen and Yacoub Habib.
How do I buy Trevena stock?
Shares of Trevena can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Trevena stock cost?
One share of Trevena stock can currently be purchased for approximately $3.99.